NASDAQ:BLRX BioLineRx (BLRX) Stock Price, News & Analysis → My next big prediction isn’t a prediction (From Porter & Company) (Ad) Free BLRX Stock Alerts $1.15 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.1550-Day Range$1.07▼$1.5652-Week Range$0.57▼$2.53Volume179,453 shsAverage Volume293,991 shsMarket Capitalization$83.31 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioLineRx alerts: Email Address BioLineRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,726.1% Upside$21.00 Price TargetShort InterestHealthy0.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector400th out of 947 stocksPharmaceutical Preparations Industry189th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingBioLineRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.00, BioLineRx has a forecasted upside of 1,726.1% from its current price of $1.15.Amount of Analyst CoverageBioLineRx has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.25% of the outstanding shares of BioLineRx have been sold short.Short Interest Ratio / Days to CoverBioLineRx has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioLineRx has recently decreased by 8.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioLineRx does not currently pay a dividend.Dividend GrowthBioLineRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLRX. Previous Next 3.6 News and Social Media Coverage News SentimentBioLineRx has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioLineRx this week, compared to 1 article on an average week.Search Interest8 people have searched for BLRX on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat Follows6 people have added BioLineRx to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLineRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BioLineRx is held by insiders.Percentage Held by InstitutionsOnly 2.01% of the stock of BioLineRx is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLineRx are expected to grow in the coming year, from ($0.98) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLineRx is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLineRx is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLineRx has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About BioLineRx Stock (NASDAQ:BLRX)BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.Read More BLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLRX Stock News HeadlinesMarch 4, 2024 | finance.yahoo.comBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale ProductionMarch 1, 2024 | investing.comBioLineRx begins phase 2 trial for pancreatic cancer treatmentMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 1, 2024 | finance.yahoo.comBLRX Mar 2024 1.000 callFebruary 28, 2024 | prnewswire.comBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 26, 2024 | finance.yahoo.comBLRX: Poster PresentationsFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 23, 2024 | ca.finance.yahoo.comBLRX May 2024 1.000 putMarch 18, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 16, 2024 | finance.yahoo.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®February 16, 2024 | prnewswire.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®December 21, 2023 | finance.yahoo.comBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell DiseaseDecember 4, 2023 | seekingalpha.comBioLineRx: Still A Buy, With Some QuestionsDecember 3, 2023 | seekingalpha.comBioLineRx: Weighing Aphexda's Breakthrough Against Financial ChallengesNovember 21, 2023 | insidermonkey.comBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call TranscriptNovember 21, 2023 | markets.businessinsider.comBioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future GrowthNovember 21, 2023 | finance.yahoo.comBLRX: A Series of Fortunate EventsNovember 20, 2023 | finance.yahoo.comBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesNovember 17, 2023 | msn.combiolinerx Q3 2023 Earnings PreviewNovember 13, 2023 | finance.yahoo.comBioLineRx to Report Third Quarter 2023 Results on November 20, 2023November 5, 2023 | msn.comWeek In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7BNovember 2, 2023 | marketwatch.comBioLineRx Shares Rise 12% After Licensing Agreement for MotixafortideOctober 31, 2023 | finanznachrichten.deMSQ Ventures: BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesOctober 31, 2023 | finance.yahoo.comBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesOctober 12, 2023 | markets.businessinsider.comBioLineRx Concludes License Deal With Guangzhou Gloria To Develop Motixafortide In AsiaOctober 12, 2023 | finance.yahoo.comBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity InvestmentOctober 9, 2023 | thestreet.comBioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment ResultsSee More Headlines Receive BLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/20/2023Today3/18/2024Next Earnings (Estimated)3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLRX CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone(728) 642-9100Fax972-8642-9101Employees49Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+1,726.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.03% Return on Assets-81.71% Debt Debt-to-Equity Ratio0.64 Current Ratio1.96 Quick Ratio1.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book1.39Miscellaneous Outstanding Shares72,440,000Free Float71,642,000Market Cap$83.31 million OptionableOptionable Beta1.40 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Philip A. Serlin CPA (Age 64)M.B.A., CPA, MBA, Chief Executive Officer Comp: $635kMs. Mali Zeevi CPA (Age 48)CPA, Chief Financial Officer Comp: $380kDr. Ella Sorani (Age 56)Chief Development Officer Comp: $457kMs. Holly W. May M.B.A. (Age 62)President of BioLineRx USA Comp: $328kMr. John LaceyHead of Corporate Communications & Investor RelationsMr. Adam Janoff Esq.General Counsel & Head of ComplianceMs. Tsipi Keren-Lehrer B.Sc.L.L.B., Head of BD & Strategic AdvisorMr. Raziel FriedTreasurer & Budgetary Control DirectorMore ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAILantern PharmaNASDAQ:LTRNPMV PharmaceuticalsNASDAQ:PMVPNeurogeneNASDAQ:NGNEInterCureNASDAQ:INCRView All CompetitorsInstitutional OwnershipPVG Asset Management CorpBought 61,840 shares on 3/12/2024Ownership: 0.085%Citadel Advisors LLCBought 200 shares on 2/15/2024Ownership: 0.000%Envestnet Asset Management Inc.Sold 11,488 shares on 2/13/2024Ownership: 0.064%NorthRock Partners LLCBought 17,125 shares on 2/8/2024Ownership: 0.024%View All Institutional Transactions BLRX Stock Analysis - Frequently Asked Questions Should I buy or sell BioLineRx stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BLRX shares. View BLRX analyst ratings or view top-rated stocks. What is BioLineRx's stock price target for 2024? 1 Wall Street analysts have issued 1 year price targets for BioLineRx's shares. Their BLRX share price targets range from $21.00 to $21.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 1,726.1% from the stock's current price. View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts. How have BLRX shares performed in 2024? BioLineRx's stock was trading at $1.57 at the beginning of the year. Since then, BLRX stock has decreased by 26.8% and is now trading at $1.15. View the best growth stocks for 2024 here. Are investors shorting BioLineRx? BioLineRx saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 183,900 shares, a decline of 8.1% from the February 14th total of 200,000 shares. Based on an average trading volume of 313,400 shares, the short-interest ratio is presently 0.6 days. View BioLineRx's Short Interest. When is BioLineRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our BLRX earnings forecast. How were BioLineRx's earnings last quarter? BioLineRx Ltd. (NASDAQ:BLRX) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.12. During the same period in the prior year, the company posted ($0.15) EPS. What other stocks do shareholders of BioLineRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE). Who are BioLineRx's major shareholders? BioLineRx's stock is owned by many different retail and institutional investors. Top institutional investors include PVG Asset Management Corp (0.09%), Envestnet Asset Management Inc. (0.06%), NorthRock Partners LLC (0.02%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of BioLineRx? Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLRX) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.